KEL
Basic information
Region (hg38): 7:142941114-142962363
Links
Phenotypes
GenCC
Source:
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Blood group, Kell system | BG | Hematologic | Variants associated with a blood group may be important in specific situations (eg, related to transfusion) | Hematologic | 7849312; 11134029; 12842980; 15373667; 16423827 |
ClinVar
This is a list of variants' phenotypes submitted to
- Kell blood group system (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the KEL gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 7 | |||||
missense | 41 | 46 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 1 | |||||
splice region | 2 | 1 | 3 | |||
non coding | 0 | |||||
Total | 1 | 0 | 41 | 7 | 5 |
Variants in KEL
This is a list of pathogenic ClinVar variants found in the KEL region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
7-142941268-C-A | not specified | Uncertain significance (Apr 28, 2022) | ||
7-142941305-G-A | not specified | Uncertain significance (Sep 22, 2021) | ||
7-142941310-T-A | not specified | Uncertain significance (Sep 14, 2022) | ||
7-142941345-G-A | Likely benign (Apr 01, 2023) | |||
7-142941365-G-A | not specified | Uncertain significance (Oct 06, 2021) | ||
7-142941370-T-C | not specified | Uncertain significance (Oct 01, 2024) | ||
7-142941386-C-A | not specified | Uncertain significance (Apr 09, 2024) | ||
7-142942466-G-T | not specified | Uncertain significance (Dec 05, 2022) | ||
7-142942529-C-T | not specified | Uncertain significance (Sep 27, 2021) | ||
7-142942882-G-A | Kell blood group system | Affects (Jul 01, 2021) | ||
7-142942882-G-T | not specified | Uncertain significance (Jul 26, 2022) | ||
7-142942883-C-A | not specified | Uncertain significance (Apr 28, 2023) | ||
7-142942917-T-C | KEL-related disorder | Benign (Dec 18, 2019) | ||
7-142942981-T-C | not specified | Uncertain significance (Jan 02, 2024) | ||
7-142943026-A-G | Kel6 antigen | Benign (May 04, 2017) | ||
7-142943285-A-G | not specified | Uncertain significance (Dec 20, 2023) | ||
7-142943327-C-T | Kell blood group system • not specified | Uncertain significance (Oct 05, 2023) | ||
7-142943481-C-T | KEL-related disorder | Likely benign (Feb 20, 2019) | ||
7-142943509-T-G | KEL-related disorder | Benign (Nov 25, 2019) | ||
7-142943556-C-A | not specified | Uncertain significance (Nov 15, 2021) | ||
7-142943574-C-T | Likely benign (May 21, 2018) | |||
7-142943589-C-T | not specified | Uncertain significance (Apr 25, 2022) | ||
7-142943600-T-A | KEL-related disorder | Benign (Jun 27, 2019) | ||
7-142943793-G-T | not specified | Uncertain significance (Oct 05, 2023) | ||
7-142943829-G-T | Benign (May 21, 2018) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
KEL | protein_coding | protein_coding | ENST00000355265 | 19 | 21568 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
3.12e-21 | 0.0287 | 125555 | 2 | 191 | 125748 | 0.000768 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | -0.648 | 449 | 412 | 1.09 | 0.0000253 | 4778 |
Missense in Polyphen | 124 | 117.33 | 1.0569 | 1482 | ||
Synonymous | -0.0906 | 164 | 163 | 1.01 | 0.00000989 | 1444 |
Loss of Function | 1.06 | 36 | 43.5 | 0.827 | 0.00000265 | 452 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000629 | 0.000629 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.00109 | 0.00109 |
Finnish | 0.00181 | 0.00157 |
European (Non-Finnish) | 0.000772 | 0.000756 |
Middle Eastern | 0.00109 | 0.00109 |
South Asian | 0.00105 | 0.00101 |
Other | 0.00103 | 0.000978 |
dbNSFP
Source:
- Function
- FUNCTION: Zinc endopeptidase with endothelin-3-converting enzyme activity. Cleaves EDN1, EDN2 and EDN3, with a marked preference for EDN3. {ECO:0000269|PubMed:10438732}.;
- Pathway
- Signaling by GPCR;Signal Transduction;Peptide ligand-binding receptors;Class A/1 (Rhodopsin-like receptors);GPCR ligand binding
(Consensus)
Recessive Scores
- pRec
- 0.218
Intolerance Scores
- loftool
- 0.234
- rvis_EVS
- -1.43
- rvis_percentile_EVS
- 4
Haploinsufficiency Scores
- pHI
- 0.243
- hipred
- N
- hipred_score
- 0.123
- ghis
- 0.452
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.849
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Kel
- Phenotype
- muscle phenotype; homeostasis/metabolism phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan);
Gene ontology
- Biological process
- proteolysis;cellular calcium ion homeostasis;regulation of cell size;cellular magnesium ion homeostasis;regulation of axon diameter;vasoconstriction;myelination;skeletal muscle fiber development;negative regulation of potassium ion transmembrane transport
- Cellular component
- plasma membrane;integral component of membrane
- Molecular function
- metalloendopeptidase activity;protein binding;metal ion binding